Infections caused by Streptococcus pneumoniae are linked to high levels of mortality and morbidity across the globe, particularly in elderly and infant population groups. Pneumococcal infections can lead to a range of health- related issues including pneumonia, meningitis, sinusitis and bacteraemia. During the COVID-19 pandemic, pneumococcal infection rates were low, however, with the resumption of international travel and relaxation of COVID-19 rules, pneumococcal infections have risen.
There are two pneumococcal vaccinations available in Australia, including pneumococcal conjugate vaccines and pneumococcal polysaccharide vaccines. During this session, we will discuss the vaccine types available and their efficacy, and how you can best support your patients.
Learning objectives
At the end of this session, participants will be able to:
1. Describe the differences between the pneumococcal vaccine products available in Australia.
2. Identify population groups eligible for the pneumococcal vaccine as part of the National Immunisation Program.
3. Outline key recommendations pharmacists can make to support the community in preventing infections caused by Streptococcus pneumoniae.
Competency standards: 1.3, 1.5, 2.1, 3.5, 3.6
